1. Home
  2. GBR vs GRI Comparison

GBR vs GRI Comparison

Compare GBR & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Concept Energy Inc

GBR

New Concept Energy Inc

HOLD

Current Price

$0.75

Market Cap

3.7M

Sector

Energy

ML Signal

HOLD

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

HOLD

Current Price

$2.40

Market Cap

3.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GBR
GRI
Founded
1978
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7M
3.3M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
GBR
GRI
Price
$0.75
$2.40
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$160.00
AVG Volume (30 Days)
89.6K
66.1K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$155,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
6.16
N/A
52 Week Low
$0.67
$0.18
52 Week High
$1.78
$6.70

Technical Indicators

Market Signals
Indicator
GBR
GRI
Relative Strength Index (RSI) 41.19 50.90
Support Level N/A $2.16
Resistance Level $0.87 $2.66
Average True Range (ATR) 0.08 0.20
MACD -0.02 -0.00
Stochastic Oscillator 11.96 47.73

Price Performance

Historical Comparison
GBR
GRI

About GBR New Concept Energy Inc

New Concept Energy Inc is a United States-based company engaged in Real Estate Operations. It intends to continue to operate and or sell its West Virginia property. It provides advisory and management services for an independent West Virginia oil and gas company. The Company seeks to establish or acquire new business operations. It operates in one segment, which is real estate rental.

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Share on Social Networks: